http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014020553-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c999da6ceacdb7989620516d686b29da
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D475-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D475-08
filingDate 2013-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49c7360fcbd7bffbeb865eb85ab96b1f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fbc862b659ed6a9803a7fd848083f817
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2d2224c6243fc804a44a3157822c3b4
publicationDate 2014-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2014020553-A1
titleOfInvention Salts of pralatrexate
abstract The present invention provides salts of Pralatrexate, in particular, sodium, lithium and potassium salts and their polymorphic forms, process for the preparation thereof, pharmaceutical compositions comprising these salts and at least one pharmaceutically acceptable excipient, and the use of pharmaceutical composition for the treatment of conditions related to human tumors.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014068599-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9783542-B2
priorityDate 2012-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011153368-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5354741-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6028071-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012061469-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5374726-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013096800-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID322112467
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226410872
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226422904
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID327979026
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226410142
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7909
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23424059
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7958
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226405837
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226415158
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128482688
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID327606158
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128806514
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID322690271
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID322930166
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID18350668
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID325458847
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11419
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128967134
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7915
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID148121
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128296525
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466705034

Total number of triples: 47.